Table 1 Basic clinical baseline table of glioma.
From: TTF2 as a potential biomarker and immunotherapy target in glioma diagnosis and prognosis
Characteristics | Low expression of TTF2 | High expression of TTF2 | P value |
|---|---|---|---|
N | 297 | 312 | |
WHO grade, n (%) | < 0.001 | ||
G2 | 169 (27.8%) | 46 (7.6%) | |
G3 | 117 (19.2%) | 125 (20.5%) | |
G4 | 11 (1.8%) | 141 (23.2%) | |
IDH status, n (%) | < 0.001 | ||
WT | 30 (4.9%) | 199 (32.7%) | |
Mut | 267 (43.8%) | 113 (18.6%) | |
Age, n (%) | < 0.001 | ||
<= 60 | 262 (43%) | 209 (34.3%) | |
> 60 | 35 (5.7%) | 103 (16.9%) | |
OS event, n (%) | < 0.001 | ||
Alive | 245 (40.2%) | 125 (20.5%) | |
Dead | 52 (8.5%) | 187 (30.7%) | |
1p/19q codeletion, n (%) | < 0.001 | ||
Non-codel | 167 (27.4%) | 292 (47.9%) | |
Codel | 130 (21.3%) | 20 (3.3%) | |
Gender, n (%) | 0.497 | ||
Female | 128 (21%) | 126 (20.7%) | |
Male | 169 (27.8%) | 186 (30.5%) | |
Race, n (%) | 0.183 | ||
Asian&Black or African American | 15 (2.5%) | 24 (3.9%) | |
White | 282 (46.3%) | 288 (47.3%) |
